In collaboration with HUTCHMED, AstraZeneca has begun their Phase III trial of a new combination treatment, savolitinib with Imfinzi, for patients with kidney cancer. The treatment is aimed at patients with papillary renal cell carcinoma (PRCC) and is an oral therapy that combines savolitinib with Imfinzi.
The trial is an international, open-label controlled, and randomized trial. The first dose of the treatment was administered to a patient last week, kicking off this phase of the trial.
Savolitinib is a highly selective small-molecule MET tyrosine kinase inhibitor, which is combined with AstraZeneca’s Imfinzi in order to inhibit programmed death-ligand one.
As of now, Sunitinib is the current standard of care for patients with PRCC. The trial is incorporating patients who have MET-driven locally advanced or metastatic PRCC and have not yet received treatment. The treatment is currently used in China to treat tumors of the lung and kidneys.
The trial’s primary endpoint is median progression-free survival (PFS), and other goals include improved survival rates, duration of response to treatment, the rate and timeline of the second progression, and disease control rate at six months of treatment.
The drug is also being analyzed as a potential treatment for a variety of tumors, including those affecting the lung and gastrointestinal tract.
Previous trial phases revealed no significant tolerability or safety issues.
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.
Comments